INOVIO PHARMACEUTICALS, INC. Deferred Tax Assets, in Process Research and Development
INOVIO PHARMACEUTICALS, INC. (INO) had Deferred Tax Assets, in Process Research and Development of $40.30 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $40.30M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $54.20M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $50.14M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $41.25M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $40.30M 10-K · filed 2026-03-12 |
| 2024-12-31 | $54.20M 10-K · filed 2026-03-12 |
| 2023-12-31 | $50.14M 10-K · filed 2025-03-18 |
| 2022-12-31 | $41.25M 10-K · filed 2024-03-06 |
| 2021-12-31 | $4.20M 10-K · filed 2023-03-01 |
| 2020-12-31 | $5.25M 10-K · filed 2022-03-01 |
| 2019-12-31 | $6.30M 10-K · filed 2021-03-01 |
| 2018-12-31 | $7.41M 10-K · filed 2020-03-12 |
| 2017-12-31 | $8.55M 10-K · filed 2019-03-12 |
| 2016-12-31 | $567.00K 10-K · filed 2018-03-14 |
| 2015-12-31 | $1.20M 10-K · filed 2017-03-15 |
| 2014-12-31 | $2.06M 10-K · filed 2016-03-14 |
| 2013-12-31 | $2.78M 10-K · filed 2015-03-16 |
| 2012-12-31 | $3.19M 10-K · filed 2014-03-17 |
| 2011-12-31 | $4.09M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |